UNSPSC 51262702: Tymazoline

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U993RH5585, chemically known as 1,4,5-dihydro-2-(2-isopropyl-5-methylphenoxymethyl)imidazol but generally known as tymazoline, which bears US NIH Compound Identifier 34154. European Medicines Agency schedules Tymazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15640MIG.

World Health Organization schedules tymazoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TYMAZOLINE remains the US FDA Preferred Term for this commodity. Tymazoline bears US NLM identifiers UMLS ID C0771442 and NCI Concept Code C95309. SMILES: O(C1C(C(C)C)CCC(C1)C)CC1=NCCN1.

UNSPSC 51262702 Tymazoline, a Commodity code, is tagged inconsistently across recent state and local opportunities, with posted solicitations addressing naloxone, drug deactivation systems, and pharmacy benefit program administration rather than tymazoline specifically. The code shows little relevant recent activity aligned with its nominal scope. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health support, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, though this RFI is exploratory and does not represent a formal competitive solicitation with binding timelines or funding commitments.

The mismatch between the code's nominal scope and the recent opportunities suggests that state and local procurement offices may be misclassifying pharmaceutical and health-related solicitations under this commodity designation. Geographic activity is limited to Florida and Texas based on the source records, with no evidence of broader regional concentration. Neither opportunity specifies set-aside designations for disadvantaged enterprises. The Seminole County naloxone procurement includes standard federal compliance requirements (E-Verify, drug-free workplace certification, and FEMA-related environmental regulations) and carries a two-year initial term with optional one-year renewal; the Texas HHS RFI remains in preliminary market-intelligence gathering and does not reflect a committed procurement action.